Retatrutide Access by State: The U.S. Trial-Site Tracker

The distinction that clears up most retatrutide searches

“Access” currently means access to a research study, not access to a prescription product. Lilly says retatrutide has not been approved by any regulatory agency. The FDA separately says retatrutide cannot be used in compounding under federal law [1,2]. Those facts do not change at a state line.

What does change is the distance between a potential participant and a study location. That is why a state tracker can be useful even though fifty separate pharmacy or cost guides are not. A resident of Texas may have many nearby recruiting locations; a resident of Alaska may have none listed. The difference is logistical research access—not a different legal status, cash price, dose, or insurance rule.

How we built the tracker

We queried the ClinicalTrials.gov API for studies whose intervention includes retatrutide and received 33 study records [3]. We then counted U.S. locations in two mutually exclusive groups:

1. Accepting or preparing to accept participants: the study was recruiting, not yet recruiting, or enrolling by invitation, and the individual location was marked recruiting or not yet recruiting.
2. Other active-study sites: the study remained active but the location was not listed as accepting participants. Most of these belonged to active, not-recruiting studies.

This is a location count, not a count of open appointment slots. A site can pause screening, narrow a cohort, or update later than the central record. ClinicalTrials.gov also warns that the U.S. government does not review or approve the safety and science of every listed study. The study contact—not a directory or telehealth seller—determines eligibility [3].

Retatrutide trial locations by state

The 142 accepting or preparing locations in this snapshot were tied to the SYNERGY-Outcomes master protocol (NCT07165028), which studies multiple agents in adults with metabolic dysfunction-associated steatotic liver disease. Retatrutide is one intervention within that protocol; a nearby site does not mean every arm or cohort is open to every candidate [4]. Another recruiting retatrutide record in the API snapshot did not list a U.S. location.

How to check a location without getting misled

Start with the study record, then verify four details in order:

• Overall study status: “Recruiting” does not guarantee that the closest location is recruiting.
• Individual site status: use the location contact attached to the record, not a third-party lead form.
• Condition and cohort: the currently recruiting U.S. locations in our snapshot were associated with a metabolic liver-disease master protocol, not a general retail weight-loss program.
• Travel burden: screening, imaging, lab work, dosing, and follow-up can require repeated visits. A location in the same state may still be impractical.

Clinical-trial participation generally does not involve buying the investigational medicine. The consent process should explain study-related costs, reimbursement, visits, possible placebo or comparator assignment, and what ordinary medical care remains the participant’s responsibility.

Why there is no honest state-by-state retatrutide price yet

A market price requires a marketed product. Retatrutide does not have one. Numbers attributed to “retatrutide cost” online describe unapproved products, research-chemical sellers, clinic claims, or guesses based on other medicines. They are not a manufacturer list price, negotiated insurer rate, or standardized pharmacy cash price.

The same logic applies to coverage. An insurer can publish a policy about investigational treatment or clinical-trial services, but that is different from covering retatrutide as a pharmacy benefit. There is currently no authorized retatrutide product for a plan to place on a formulary [1].

Lilly has announced positive topline results from multiple pivotal studies and said it plans a U.S. submission in the first quarter of 2027 [5,6]. Submission is not approval. If the product is eventually approved, price, labeling, payer policies, distribution, and patient-support programs would all need fresh reporting.

What the phase 3 announcements add—and what they do not

The access tracker answers where research is happening. The phase 3 program answers a different question: what has been observed in defined trial populations.

For the earlier peer-reviewed phase 2 evidence, see our retatrutide mechanism review. For the development map beyond a single indication, see the retatrutide pipeline guide.

When this tracker should be updated

The state table should be regenerated when ClinicalTrials.gov adds or changes locations, when a major study changes recruitment status, or when a regulatory decision changes the meaning of “access.” It should not be refreshed by changing the date while leaving the data untouched.

The next decisive commercial milestone would be an agency decision after submission. Until then, the durable answer is simple: research geography varies by state; commercial availability does not.